Novo Nordisk A/S $NVO Stock Position Lifted by Banque Pictet & Cie SA

Banque Pictet & Cie SA grew its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 68.2% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 86,648 shares of the company’s stock after purchasing an additional 35,142 shares during the period. Banque Pictet & Cie SA’s holdings in Novo Nordisk A/S were worth $4,409,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also modified their holdings of the company. Lodestone Wealth Management LLC acquired a new stake in Novo Nordisk A/S in the fourth quarter worth about $63,000. Frank Rimerman Advisors LLC increased its stake in Novo Nordisk A/S by 38.8% during the 4th quarter. Frank Rimerman Advisors LLC now owns 30,069 shares of the company’s stock valued at $1,530,000 after buying an additional 8,403 shares during the period. Investment Partners Asset Management Inc. acquired a new position in Novo Nordisk A/S during the 4th quarter valued at about $409,000. Heirloom Wealth Management raised its position in shares of Novo Nordisk A/S by 52.7% during the 4th quarter. Heirloom Wealth Management now owns 211,886 shares of the company’s stock worth $10,781,000 after buying an additional 73,171 shares in the last quarter. Finally, Archford Capital Strategies LLC bought a new stake in shares of Novo Nordisk A/S during the 4th quarter worth about $266,000. 11.54% of the stock is currently owned by institutional investors.

Novo Nordisk A/S News Roundup

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: U.K. drug regulator NICE recommended Wegovy for heart‑disease prevention, expanding NHS access by about 1.2 million people — a material commercial win that supports longer‑term demand for Wegovy. Novo Nordisk shares rise after Wegovy recommended by Britain’s drug price regulator
• Positive Sentiment: Management launched a Wegovy subscription pricing model and expanded telehealth partnerships to lower out‑of‑pocket costs and improve adherence — a tactical move to protect market share and pricing power in self‑pay segments. NVO Launches Wegovy Subscription Plan, Boosts Access, Stock Up
• Positive Sentiment: Novo released a cross‑trial comparison (ORION) showing oral Wegovy produced greater mean weight loss and fewer dropouts versus Lilly’s pill — messaging aimed at bluntly defending the oral franchise as Lilly begins commercialization. Novo Nordisk says Wegovy pill outperforms Lilly’s oral GLP-1 in cross-trial comparison
• Positive Sentiment: Pipeline progress continues: Novo is advancing next‑generation metabolic candidates (including a triple‑agonist program) through early clinical trials, which supports longer‑term upside beyond current GLP‑1 competition. Novo Nordisk Triple Agonist Progress Spurs Questions On Valuation Gap
• Neutral Sentiment: BMO Capital reiterated a Market Perform (hold) rating with a $45 price target — signaling analysts see limited near‑term upside while acknowledging the Wegovy pill momentum. BMO Capital Maintains a Hold Rating on Novo Nordisk (NVO)
• Neutral Sentiment: Market coverage notes the shares edged higher and held up early despite Lilly’s approval — suggesting investors had partially priced in competitive pressure. Novo Nordisk shares resilient as FDA approves Eli Lilly GLP-1 weight-loss pill to intensify competition
• Negative Sentiment: FDA approval of Eli Lilly’s oral GLP‑1 (Foundayo/orforglipron) and an expected multi‑billion dollar commercial debut create direct pricing and market‑share pressure on Novo’s Wegovy/Ozempic franchises. Analysts and traders are pricing a more contested oral market going forward. Wall Street sees multi-billion dollar debut for Lilly’s obesity pill despite Novo lead
• Negative Sentiment: Broader policy/regulatory risk: reports the administration is considering tariffs of up to 100% on branded drug imports could create volatility and uncertainty for multinational drugmakers if no concessions/deals are struck. Trump administration prepares up to 100% pharmaceutical tariffs on some imported drugs
• Negative Sentiment: Analyst commentary highlights intensifying duopoly dynamics with Eli Lilly, product gaps in injectables vs. Lilly, and patent/competitive lifecycle concerns — risks that could pressure growth and valuation if market share slips. Novo Nordisk: Competing In A Duopoly

Novo Nordisk A/S Trading Up 1.2%

NYSE:NVO opened at $36.92 on Friday. The company has a quick ratio of 0.57, a current ratio of 0.80 and a debt-to-equity ratio of 0.61. Novo Nordisk A/S has a 1-year low of $35.12 and a 1-year high of $81.44. The firm has a market capitalization of $164.86 billion, a price-to-earnings ratio of 10.64, a price-to-earnings-growth ratio of 8.63 and a beta of 0.73. The stock has a fifty day simple moving average of $43.93 and a 200 day simple moving average of $49.98.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings data on Tuesday, February 3rd. The company reported $1.01 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.90 by $0.11. Novo Nordisk A/S had a return on equity of 68.91% and a net margin of 33.03%.The firm had revenue of $12.43 billion for the quarter, compared to the consensus estimate of $11.97 billion. Sell-side analysts forecast that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Dividend Announcement

The company also recently declared a dividend, which will be paid on Wednesday, April 8th. Stockholders of record on Monday, March 30th will be issued a dividend of $1.2751 per share. The ex-dividend date is Monday, March 30th. This represents a dividend yield of 723.0%. Novo Nordisk A/S’s payout ratio is currently 50.43%.

Analyst Upgrades and Downgrades

Several research firms have recently issued reports on NVO. Argus reiterated a “hold” rating on shares of Novo Nordisk A/S in a report on Monday, December 8th. JPMorgan Chase & Co. reissued a “neutral” rating on shares of Novo Nordisk A/S in a report on Tuesday, February 24th. Wolfe Research began coverage on Novo Nordisk A/S in a research report on Thursday, March 26th. They issued a “peer perform” rating for the company. Morgan Stanley raised Novo Nordisk A/S from an “underweight” rating to an “equal weight” rating and set a $40.00 price target for the company in a research note on Tuesday, March 3rd. Finally, TD Cowen cut Novo Nordisk A/S from a “buy” rating to a “hold” rating and set a $42.00 price target on the stock. in a research report on Tuesday, March 10th. Four investment analysts have rated the stock with a Buy rating, nineteen have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Novo Nordisk A/S presently has an average rating of “Hold” and a consensus price target of $65.56.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.